Last reviewed · How we verify
methyphenidate
methyphenidate is a Small molecule drug developed by IRCCS Eugenio Medea. It is currently in Phase 2 development. Also known as: Drug treatment.
Methyphenidate is a medication that has been studied in clinical trials for various conditions, including obesity, apathy, emotional dysregulation, externalizing problems, and oppositional defiant disorder. It has been used as an intervention in studies examining its effectiveness in conjunction with other treatments, such as weight loss interventions and medical crisis counseling.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | methyphenidate |
|---|---|
| Also known as | Drug treatment |
| Sponsor | IRCCS Eugenio Medea |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders
- Role of Apathy in the Effectiveness of Weight Loss Interventions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- methyphenidate CI brief — competitive landscape report
- methyphenidate updates RSS · CI watch RSS
- IRCCS Eugenio Medea portfolio CI
Frequently asked questions about methyphenidate
What is methyphenidate?
Who makes methyphenidate?
Is methyphenidate also known as anything else?
What development phase is methyphenidate in?
Related
- Manufacturer: IRCCS Eugenio Medea — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Drug treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing